You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

LIPITOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lipitor, and what generic alternatives are available?

Lipitor is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lipitor

A generic version of LIPITOR was approved as atorvastatin calcium by SUN PHARM INDS LTD on November 30th, 2011.

  Try a Trial

Drug patent expirations by year for LIPITOR
Drug Prices for LIPITOR

See drug prices for LIPITOR

Drug Sales Revenue Trends for LIPITOR

See drug sales revenues for LIPITOR

Recent Clinical Trials for LIPITOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NYU Langone HealthPhase 4
Gannex Pharma Co., Ltd.Phase 1
Montefiore Medical CenterN/A

See all LIPITOR clinical trials

Pharmacology for LIPITOR

US Patents and Regulatory Information for LIPITOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-001 Dec 17, 1996 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-004 Apr 7, 2000 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-002 Dec 17, 1996 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-003 Dec 17, 1996 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LIPITOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-003 Dec 17, 1996 ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-004 Apr 7, 2000 ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-002 Dec 17, 1996 ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-001 Dec 17, 1996 ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-002 Dec 17, 1996 ⤷  Try a Trial ⤷  Try a Trial
Upjohn LIPITOR atorvastatin calcium TABLET;ORAL 020702-004 Apr 7, 2000 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LIPITOR

See the table below for patents covering LIPITOR around the world.

Country Patent Number Title Estimated Expiration
Finland 88617 ⤷  Try a Trial
Philippines 26330 7-(substituted-pyrrolyl)-3,5-di-hydroxyheptanoic acids ⤷  Try a Trial
Norway 309898 ⤷  Try a Trial
Ireland 871197 ⤷  Try a Trial
Croatia P960339 CRYSTALLINE /R- (R*, R*)/-2-(4-FLUOROPHENYL) -BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-/(PHENYLAMINO) CARBONYL/-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT ⤷  Try a Trial
Germany 69523978 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LIPITOR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 300689 Netherlands ⤷  Try a Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0720599 92545 Luxembourg ⤷  Try a Trial PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
1003503 C01003503/01 Switzerland ⤷  Try a Trial PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006
0247633 SPC/GB97/011 United Kingdom ⤷  Try a Trial SPC/GB97/011: 20070529, EXPIRES: 20111106
1003503 05C0048 France ⤷  Try a Trial PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
0247633 62/1997 Austria ⤷  Try a Trial PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.